ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Monaco Asset Management SAM

Monaco Asset Management SAM cut its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 10.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 135,561 shares of the company’s stock after selling 15,000 shares during the quarter. Monaco Asset Management SAM owned 0.19% of ORIC Pharmaceuticals worth $1,094,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ORIC. Victory Capital Management Inc. lifted its stake in ORIC Pharmaceuticals by 4.1% during the third quarter. Victory Capital Management Inc. now owns 99,750 shares of the company’s stock worth $1,022,000 after purchasing an additional 3,900 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in ORIC Pharmaceuticals during the third quarter worth $132,000. Intech Investment Management LLC bought a new position in ORIC Pharmaceuticals during the third quarter worth $200,000. Charles Schwab Investment Management Inc. lifted its stake in ORIC Pharmaceuticals by 152.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock worth $4,205,000 after purchasing an additional 247,863 shares during the last quarter. Finally, Alkeon Capital Management LLC lifted its stake in ORIC Pharmaceuticals by 2.6% during the third quarter. Alkeon Capital Management LLC now owns 3,904,096 shares of the company’s stock worth $40,017,000 after purchasing an additional 100,000 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors.

Insider Activity at ORIC Pharmaceuticals

In related news, insider Pratik S. Multani sold 8,850 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $73,278.00. Following the transaction, the insider now owns 46,765 shares in the company, valued at $387,214.20. This trade represents a 15.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jacob Chacko sold 24,660 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $204,184.80. Following the transaction, the chief executive officer now owns 778,648 shares in the company, valued at $6,447,205.44. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,361 shares of company stock worth $350,749 over the last quarter. 5.55% of the stock is currently owned by company insiders.

ORIC Pharmaceuticals Price Performance

Shares of ORIC stock opened at $7.70 on Friday. ORIC Pharmaceuticals, Inc. has a 12-month low of $6.33 and a 12-month high of $15.40. The firm has a market capitalization of $546.91 million, a price-to-earnings ratio of -4.23 and a beta of 1.25. The business has a 50 day simple moving average of $9.19 and a 200 day simple moving average of $9.35.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.01. On average, equities analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ORIC shares. Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research report on Monday, January 13th. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st. JPMorgan Chase & Co. boosted their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $18.86.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.